ID   MeT-5A
AC   CVCL_3749
SY   MeT 5A; MeT5A; Met5A; MET5A; Mesothelial cells transfected with pRSV-T 5A
DR   CLO; CLO_0007680
DR   EFO; EFO_0001218
DR   ATCC; CRL-9444
DR   BCRC; 60352
DR   BioSample; SAMN03471216
DR   GEO; GSM49613
DR   GEO; GSM139667
DR   GEO; GSM139668
DR   GEO; GSM139669
DR   GEO; GSM139760
DR   GEO; GSM139761
DR   GEO; GSM3684948
DR   IZSLER; BS CL 214
DR   PRIDE; PXD033058
DR   Wikidata; Q54905322
RX   Patent=US4885238;
RX   PubMed=2541616;
RX   PubMed=9533946;
RX   PubMed=15920167;
RX   PubMed=17331233;
RX   PubMed=21454801;
RX   PubMed=22576795;
RX   PubMed=24926545;
RX   PubMed=26011428;
RX   PubMed=28553954;
RX   PubMed=33567673;
RX   PubMed=34663305;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9444.
CC   Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [Note=pRSV-T].
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Lung, pleura; UBERON=UBERON_0000977.
CC   Cell type: Mesothelial cell; CL=CL_0000077.
ST   Source(s): ATCC; IZSLER
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11,13
ST   D16S539: 12
ST   D18S51: 15,23
ST   D19S433: 15
ST   D21S11: 31.2
ST   D2S1338: 18,19
ST   D3S1358: 17,18
ST   D5S818: 12
ST   D7S820: 10
ST   D8S1179: 12,13
ST   FGA: 22,23
ST   Penta D: 10,11
ST   Penta E: 10,16
ST   TH01: 6,9.3
ST   TPOX: 8 (ATCC)
ST   TPOX: 8,11 (IZSLER)
ST   vWA: 15,18
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Adult
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 23
//
RX   Patent=US4885238;
RA   Reddel R.R., Yang K., Rhim J.S., Brash D.E., Su R.T., Lechner J.F.,
RA   Gerwin B.I., Harris C.C., Amstad P.;
RT   "Immortalized human bronchial epithelial mesothelial cell lines.";
RL   Patent number US4885238, 05-Dec-1989.
//
RX   PubMed=2541616;
RA   Ke Y., Reddel R.R., Gerwin B.I., Reddel H.K., Somers A.N.A.,
RA   McMenamin M.G., LaVeck M.A., Stahel R.A., Lechner J.F., Harris C.C.;
RT   "Establishment of a human in vitro mesothelial cell model system for
RT   investigating mechanisms of asbestos-induced mesothelioma.";
RL   Am. J. Pathol. 134:979-991(1989).
//
RX   PubMed=9533946; DOI=10.1165/ajrcmb.18.4.2943;
RA   Kahlos K., Anttila S., Asikainen T.M., Kinnula K., Raivio K.O.,
RA   Mattson K., Linnainmaa K., Kinnula V.L.;
RT   "Manganese superoxide dismutase in healthy human pleural mesothelium
RT   and in malignant pleural mesothelioma.";
RL   Am. J. Respir. Cell Mol. Biol. 18:570-580(1998).
//
RX   PubMed=15920167; DOI=10.1016/S0002-9440(10)62492-3;
RA   Gordon G.J., Rockwell G.N., Jensen R.V., Rheinwald J.G.,
RA   Glickman J.N., Aronson J.P., Pottorf B.J., Nitz M.D., Richards W.G.,
RA   Sugarbaker D.J., Bueno R.;
RT   "Identification of novel candidate oncogenes and tumor suppressors in
RT   malignant pleural mesothelioma using large-scale transcriptional
RT   profiling.";
RL   Am. J. Pathol. 166:1827-1840(2005).
//
RX   PubMed=17331233; DOI=10.1186/1471-2164-8-62;
RA   Nymark P., Lindholm P.M., Korpela M.V., Lahti L., Ruosaari S.,
RA   Kaski S., Hollmen J., Anttila S., Kinnula V.L., Knuutila S.;
RT   "Gene expression profiles in asbestos-exposed epithelial and
RT   mesothelial lung cell lines.";
RL   BMC Genomics 8:62.1-62.14(2007).
//
RX   PubMed=21454801; DOI=10.1165/rcmb.2010-0282OC;
RA   Shukla A., Barrett T.F., MacPherson M.B., Hillegass J.M.,
RA   Fukagawa N.K., Swain W.A., O'Byrne K.J., Testa J.R., Pass H.I.,
RA   Faux S.P., Mossman B.T.;
RT   "An extracellular signal-regulated kinase 2 survival pathway mediates
RT   resistance of human mesothelioma cells to asbestos-induced injury.";
RL   Am. J. Respir. Cell Mol. Biol. 45:906-914(2011).
//
RX   PubMed=22576795; DOI=10.3892/or.2012.1763;
RA   Ashinuma H., Takiguchi Y., Kitazono S., Kitazono-Saitoh M.,
RA   Kitamura A., Chiba T., Tada Y., Kurosu K., Sakaida E., Sekine I.,
RA   Tanabe N., Iwama A., Yokosuka O., Tatsumi K.;
RT   "Antiproliferative action of metformin in human lung cancer cell
RT   lines.";
RL   Oncol. Rep. 28:8-14(2012).
//
RX   PubMed=24926545; DOI=10.1097/JTO.0000000000000202;
RA   Riquelme E., Suraokar M.B., Rodriguez J., Mino B., Lin H.Y.,
RA   Rice D.C., Tsao A., Wistuba I.I.;
RT   "Frequent coamplification and cooperation between C-MYC and PVT1
RT   oncogenes promote malignant pleural mesothelioma.";
RL   J. Thorac. Oncol. 9:998-1007(2014).
//
RX   PubMed=26011428; DOI=10.1111/cas.12698;
RA   Hakiri S., Osada H., Ishiguro F., Murakami H., Murakami-Tonami Y.,
RA   Yokoi K., Sekido Y.;
RT   "Functional differences between wild-type and mutant-type
RT   BRCA1-associated protein 1 tumor suppressor against malignant
RT   mesothelioma cells.";
RL   Cancer Sci. 106:990-999(2015).
//
RX   PubMed=28553954; DOI=10.1038/onc.2017.147;
RA   Kato T., Sato T., Yokoi K., Sekido Y.;
RT   "E-cadherin expression is correlated with focal adhesion kinase
RT   inhibitor resistance in merlin-negative malignant mesothelioma
RT   cells.";
RL   Oncogene 36:5522-5531(2017).
//
RX   PubMed=33567673; DOI=10.3390/cancers13040685;
RA   Keller M., Reis K., Hjerpe A., Dobra K., Aspenstrom P.;
RT   "Cytoskeletal organization correlates to motility and invasiveness of
RT   malignant mesothelioma cells.";
RL   Cancers (Basel) 13:685.1-685.20(2021).
//
RX   PubMed=34663305; DOI=10.1186/s12935-021-02248-5;
RA   Sato T., Nakanishi H., Akao K., Okuda M., Mukai S., Kiyono T.,
RA   Sekido Y.;
RT   "Three newly established immortalized mesothelial cell lines exhibit
RT   morphological phenotypes corresponding to malignant mesothelioma
RT   epithelioid, intermediate, and sarcomatoid types, respectively.";
RL   Cancer Cell Int. 21:546.1-546.11(2021).
//